Celcuity (CELC)

• Market cap: $4.66B
• 1 day: 4.45%
• 5 days: -0.71%
• 1 month: 23.61%
• 3 months: 91.68%
• 6 months: 737.98%
• Year to date: 701.6%
• 1 year: 734.66%
• 5 years: 854.22%
• 10 years: 636.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Employees: 87